RT Journal Article
SR Electronic
T1 Respiratory Syncytial Virus (RSV) Hospital Admission Rates and Patients’ Characteristics Before the Age of Two in England, 2015-2019
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.04.23288132
DO 10.1101/2023.04.04.23288132
A1 Fonseca, Maria João
A1 Hagenaars, Saskia
A1 Bangert, Mathieu
A1 Flach, Clare
A1 Hudson, Richard
YR 2023
UL http://medrxiv.org/content/early/2023/04/04/2023.04.04.23288132.abstract
AB Background A granular understanding of respiratory syncytial virus (RSV) burden in England is needed to prepare for new RSV prevention strategies. We estimated the rates of RSV hospital admissions in infants before age two in England and describe baseline characteristics.Methods A birth cohort of all infants born between 01/03/2015 and 28/02/2017 (n=449,591) was established using Clinical Practice Research Datalink-Hospital Episode Statistics. Case cohorts included infants with an admission for 1) RSV-coded, 2) bronchiolitis-coded, 3) any respiratory tract infection (RTI)-coded <24 months and 4) RSV-predicted by an algorithm <12 months. Baseline characteristics were described in case and comparative cohorts (infants without corresponding admission). Cumulative incidence and admission rates were calculated. Multiple linear regression was used to estimate the proportion of RTI healthcare visits attributable to RSV.Results The RSV-coded/RSV-predicted case cohorts were composed of 4,813/12,694 infants (cumulative incidence: 1.1%/2.8%). Case cohort infants were more likely to have low birth weight, comorbidities and to be born during RSV season than comparative cohort infants, yet >77% were term healthy infants and >54% born before the RSV season. During the first year of life, 11.6 RSV-coded and 34.4 RSV-predicted hospitalizations occurred per 1,000 person-years. Overall, >25% of unspecified lower RTI admissions were estimated to be due to RSV.Conclusions In England, one in 91 infants had an RSV-coded admission, likely underestimated by ∼3-fold. Most infants were term healthy infants born before the RSV season. To decrease the total burden of RSV at the population level, immunization programs need to protect all infants.Competing Interest StatementMJF, SH and CF are IQVIA employees, with nothing to disclose. MB and RH are employees of Sanofi and may hold stocks in the company. This study was funded by Sanofi and AstraZeneca.Funding StatementThis study was funded by Sanofi and AstraZeneca.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of The Medicines and Healthcare products Regulatory Agency (MHRA) Independent Scientific Advisory Committee (ISAC) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors